Related Experiment Video
Updated: Aug 11, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Changing Epidemiology of Severe Pneumococcal Pneumonia in Adults at Tertiary Hospital between 2010-2024
Sang-Ho Choi1, Jin Won Huh2, Sang-Bum Hong2
1Department of Infectious diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Background:
The epidemiology of pneumococcal pneumonia can be influenced by vaccine implementation, serotype replacement, and viral circulation. We aimed to investigate 15-year trends in the epidemiological and clinical characteristics of severe pneumococcal pneumonia patients requiring intensive care unit (ICU) admission.
Methods:
We analyzed data from a prospective cohort of adult patients with severe pneumonia admitted to the 28-bed medical ICU of a 2,700-bed tertiary hospital in South Korea between 2010 and 2024. Temporal changes in incidence, resistance to antimicrobial agents, frequency of co-infections, and mortality were evaluated across three 5-year periods.
Results:
Among 2,511 ICU patients with severe pneumonia, 140 (5.6%) had pneumococcal infections. The proportion of pneumococcal cases decreased from 9.9% in 2010-2014 to 4.2% in 2015-2019, and further to 2.2% in 2020-2024 (p<0.001 for trend). Conversely, ceftriaxone non-susceptibility rates rose sharply from 4.8% to 16.7% and 45.5% across the same periods (p<0.001). Co-infections were frequent and increased significantly, largely due to respiratory viruses, with rates of 48.9%, 61.8%, and 77.8%, respectively (p=0.02). Influenza was the predominant co-pathogen during 2015-2019, whereas SARS-CoV-2 was most frequent in 2020-2024. The 90-day mortality rates remained stable over time (29.5%, 38.2%, and 27.8%, p=0.64).
Conclusions:
In this single-center ICU cohort, the proportion of severe pneumococcal pneumonia cases decreased over the 15-year period, whereas ceftriaxone non-susceptibility and viral co-infections became more frequent. These trends should be interpreted cautiously given the lack of serotype and individual vaccination data and incomplete susceptibility results. Continued surveillance of pneumococcal disease, antimicrobial resistance, and respiratory co-infections is warranted.
Related Concept Videos
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:14Atypical Pneumonia